Inventiva's lanifibranor is the next in line candidate in MASH, with its phase 3 (NATiV3) trial now fully recruited, locking in a topline readout for 2H26. The program is de-risked by a robust phase 2b, showing competitive fibrosis response rates and strong HbA1c reduction— a key differentiator for the large MASH + T2D population. With oral dosing and clean safety, lanifibranor is well-positioned to capture a meaningful share of the validated MASH commercial opportunity. A € 348m structured fina...
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference Daix (France), New York City (New York, United States), August 11, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that Jason Campagna, MD, PhD, President of R&D and Chief Medical Officer, and David Nikodem, PhD, Vice President of US Operations will participate in a fireside chat at the Canacc...
Inventiva Participera à la « Canaccord Genuity 45th Annual Growth Conference » Daix (France), New York City (New York, Etats-Unis), le 11 aout 2025 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd'hui que Jason Campagna, MD, PhD, Président de la R&D et Directeur Médical, et David Nikodem, PhD, Vice-Président des opérations aux États-Unis, participeront à un « fireside chat » lors d...
GTT: Monthly disclosure of the total number of voting rights and shares composing the share capital Monthly disclosure of the total number of voting rights and shares composing the share capital Articles L. 233-8-II of the French Commercial Code and 223-16 of the General Regulation of the Autorité des Marchés Financiers Saint-Rémy-lès-Chevreuse, August 4, 2025 DateTotal number of sharesTheoretical total number of voting rights1Net total number of voting rights2July 31, 202537,117,77237,117,77237,064,515 Investor Relations Contact / 87 1 Calculated on ...
GTT : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Articles L. 233-8-II du Code de commerce et 223-16 du Règlement général de l’Autorité des marchés financiers Saint-Rémy-lès-Chevreuse, le 4 août 2025 DateNombre total d’actions composant le capitalNombre total de droits de vote théoriques1Nombre total de droits de vote nets231 juillet 202537 117 77237 117 77237 064 515 Contact Relations Investisseurs : / 87 ...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Keple...
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), New York (New York, Etats-Unis), le 31 juillet 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite non alcoolique ("NASH") et d’autres maladies avec un besoin médical non satisfait significatif, annonce aujourd’hui le bilan semestriel de son contrat de liquidité conclu avec Kepler Cheuvreux. Au titre du contrat de...
GTT completes the acquisition of Danelec and strengthens its leadership in maritime digitalisation GTT completes the acquisition of Danelec and strengthens its leadership in maritime digitalisation GTT finalises the acquisition of Danelec, a global leader in maritime safety and digital performance solutionsSignificant growth and synergy potentialAccretive impact on the Group’s earnings per share from year oneCasper Jensen appointed Executive Vice President Digital Paris, 31 July 2025 – GTT, a technology and engineering group specialising in containment systems for liquefied gases, today a...
GTT finalise l’acquisition de Danelec et renforce son leadership dans la digitalisation du monde maritime GTT finalise l’acquisition de Danelec et renforce son leadership dans la digitalisation du monde maritime GTT finalise l’acquisition de Danelec, un leader mondial des solutions digitales dédiées à la sécurité maritime et à la performance opérationnelle des naviresFort potentiel de croissance et de synergiesEffet relutif dès la première année sur le résultat net par action du Groupe Casper Jensen est nommé Executive Vice President Digital Paris, le 31 juillet 2025 - GTT, groupe de tech...
Inventiva reported uneventful preliminary 1H25 cash and revenues with revenues of € 4.5m, and a cash position of € 122.1m and € 24.6m in short term deposits (YE24: € 96.6m), and confirmed its cash runway to the end of 3Q26. This funding should take the company to completion of the ongoing 72-week phase 3 (NATiV3) trial of lanifibranor (pan-PPAR agonist) in MASH (F2/F3), which completed recruitment in April 2025. With the funding overhang lifted, a fully recruited phase 3 trial in MASH, as well a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.